{"id":264390,"date":"2020-08-07T00:18:52","date_gmt":"2020-08-07T04:18:52","guid":{"rendered":"https:\/\/canadianinquirer.net\/v1\/?p=264390"},"modified":"2020-08-07T00:18:52","modified_gmt":"2020-08-07T04:18:52","slug":"japan-sends-avigan-for-covid-19-patients-in-ph","status":"publish","type":"post","link":"https:\/\/canadianinquirer.net\/v1\/2020\/08\/07\/japan-sends-avigan-for-covid-19-patients-in-ph\/","title":{"rendered":"Japan sends Avigan for Covid-19 patients in PH"},"content":{"rendered":"<figure id=\"attachment_264391\" aria-describedby=\"caption-attachment-264391\" style=\"width: 1280px\" class=\"wp-caption alignnone\"><a href=\"https:\/\/canadianinquirer.net\/v1\/wp-content\/uploads\/2020\/08\/medications-257349_1280.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-264391 size-full\" src=\"https:\/\/canadianinquirer.net\/v1\/wp-content\/uploads\/2020\/08\/medications-257349_1280.jpg\" alt=\"\" width=\"1280\" height=\"847\" srcset=\"https:\/\/canadianinquirer.net\/v1\/wp-content\/uploads\/2020\/08\/medications-257349_1280.jpg 1280w, https:\/\/canadianinquirer.net\/v1\/wp-content\/uploads\/2020\/08\/medications-257349_1280-300x199.jpg 300w, https:\/\/canadianinquirer.net\/v1\/wp-content\/uploads\/2020\/08\/medications-257349_1280-768x508.jpg 768w, https:\/\/canadianinquirer.net\/v1\/wp-content\/uploads\/2020\/08\/medications-257349_1280-1024x678.jpg 1024w\" sizes=\"auto, (max-width: 1280px) 100vw, 1280px\" \/><\/a><figcaption id=\"caption-attachment-264391\" class=\"wp-caption-text\">Some researches have revealed that Avigan, developed by a subsidiary of Japan-based Fujifilm Holdings Corp., is seen as an effective drug in treating Covid-19. (Pixabay photo)<\/figcaption><\/figure>\n<p><strong>MANILA<\/strong>\u00a0\u2013 The Philippine government has received from Tokyo the anti-viral medicine Avigan, a potential treatment against coronavirus disease 2019 (Covid-19), the Japanese embassy in Manila said Thursday.<\/p>\n<p>The medicine, whose generic name is favipiravir, was turned over to the Department of Health on August 6 and will be allotted for 100 patients who are part of the Avigan clinical trial.<\/p>\n<p>&#8220;Japan hopes that this ongoing cooperation with the Philippines would further contribute to the advancement of clinical research to contain the Covid-19 pandemic,&#8221; the embassy said in a statement.<\/p>\n<p>Some researches have revealed that Avigan, developed by a subsidiary of Japan-based Fujifilm Holdings Corp., is seen as an effective drug in treating Covid-19.<\/p>\n<p>It has drawn interest from many countries for its potential to counter viral replication.<\/p>\n<p>In\u00a0Japan, the drug showed some promise in treating Covid-19 infected patients as some of them recovered after taking it.<\/p>\n<p>However, health experts cautioned against its use because the drug has one dangerous potential side effect &#8212; birth defects.<\/p>\n<p>The arrival of the drug is part of Tokyo&#8217;s emergency grant aid to countries severely affected by the pandemic.<\/p>\n<p>Each recipient government acknowledged Avigan\u2019s proper usage and prescription in view of its known adverse side effects, the embassy said.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>MANILA\u00a0\u2013 The Philippine government has received from Tokyo the anti-viral medicine Avigan, a potential treatment against coronavirus disease 2019 (Covid-19), &hellip;<\/p>\n","protected":false},"author":44,"featured_media":264391,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16,95],"tags":[],"class_list":["post-264390","post","type-post","status-publish","format-standard","has-post-thumbnail","category-news","category-news-ph","mauthors-joyce-ann-l-rocamora","mauthors-philippine-news-agency"],"_links":{"self":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts\/264390","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/users\/44"}],"replies":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/comments?post=264390"}],"version-history":[{"count":1,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts\/264390\/revisions"}],"predecessor-version":[{"id":264392,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts\/264390\/revisions\/264392"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/media\/264391"}],"wp:attachment":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/media?parent=264390"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/categories?post=264390"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/tags?post=264390"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}